Literature DB >> 16487409

Intestinal epithelial cell signalling and host-derived negative regulators under chronic inflammation: to be or not to be activated determines the balance towards commensal bacteria.

D Haller1.   

Abstract

Advancing knowledge regarding the cellular mechanisms of intestinal inflammation has led to a better understanding of the disease pathology in patients with chronic disorders of the gut including inflammatory bowel disease, coeliac disease, lymphocytic colitis and irritable bowel syndrome. An emerging new paradigm suggests that changes in the homeostasis of bacteria- and host-derived signal transduction at the epithelial cell level may lead to functional and immune disturbances of the intestinal epithelium. It has become clear from numerous studies that enteric bacteria are a critical component in the development and prevention/treatment of chronic intestinal inflammation. Signal-specific activation of mitogen-activated protein kinases (MAPK), interferon-regulated factors (IRF) and the transcription factor NF-kappaB through pattern recognition receptor signalling effectively induce inflammatory defence mechanisms. Unbalanced activation of these innate signalling pathways because of host genetic predispositions and/or the lack of adequate anti-inflammatory feedback mechanisms may turn a physiological response into a pathological situation including failure of bacterial clearance and development of chronic inflammation. Host-derived regulators from the immune and enteric nerve system crosstalk to the innate signalling network of the intestinal epithelium in order to shape the extent and duration of inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487409     DOI: 10.1111/j.1365-2982.2006.00762.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  9 in total

Review 1.  Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness.

Authors:  Jessica A Clark; Craig M Coopersmith
Journal:  Shock       Date:  2007-10       Impact factor: 3.454

Review 2.  Microbial host interactions in IBD: implications for pathogenesis and therapy.

Authors:  R Balfour Sartor; Marcus Muehlbauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

Review 3.  Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens.

Authors:  Sarah Lebeer; Jos Vanderleyden; Sigrid C J De Keersmaecker
Journal:  Nat Rev Microbiol       Date:  2010-03       Impact factor: 60.633

4.  Characterization of intestinal inflammation and identification of related gene expression changes in mdr1a(-/-) mice.

Authors:  Y E M Dommels; C A Butts; S Zhu; M Davy; S Martell; D Hedderley; M P G Barnett; W C McNabb; N C Roy
Journal:  Genes Nutr       Date:  2007-09-27       Impact factor: 5.523

5.  Immunohistochemical localization of Clara cell secretory proteins (CC10-CC26) and Annexin-1 protein in rat major salivary glands.

Authors:  Maria Paola Cecchini; Flavia Merigo; Mirko Cristofoletti; Francesco Osculati; Andrea Sbarbati
Journal:  J Anat       Date:  2009-05       Impact factor: 2.610

6.  Regulation of the polymeric immunoglobulin receptor by the classical and alternative NF-κB pathways in intestinal epithelial cells.

Authors:  M E C Bruno; A L Frantz; E W Rogier; F-E Johansen; C S Kaetzel
Journal:  Mucosal Immunol       Date:  2011-03-30       Impact factor: 7.313

7.  Metabolomic applications to decipher gut microbial metabolic influence in health and disease.

Authors:  François-Pierre J Martin; Sebastiano Collino; Serge Rezzi; Sunil Kochhar
Journal:  Front Physiol       Date:  2012-04-26       Impact factor: 4.566

8.  The complex exogenous RNA spectra in human plasma: an interface with human gut biota?

Authors:  Kai Wang; Hong Li; Yue Yuan; Alton Etheridge; Yong Zhou; David Huang; Paul Wilmes; David Galas
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

9.  Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease.

Authors:  Jun Shen; Yu-qi Qiao; Zhi-hua Ran; Tian-rong Wang
Journal:  Int J Med Sci       Date:  2013-01-03       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.